Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals Inc    ARWR

ARROWHEAD PHARMACEUTICALS INC

(ARWR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Arrowhead Shares Up, Orion Group Falls After Hours on S&P SmallCap 600 Moves

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/20/2019 | 08:05pm EDT

By Josh Beckerman

Arrowhead Pharmaceuticals shares rose 7% to $20.28 as the company was selected to join the S&P SmallCap 600, effective Friday.

Meanwhile, S&P Dow Jones Indices said is removing construction company Orion Group Holdings from the SmallCap 600, as it "has a market capitalization that is no longer representative of the small-cap market space."

Orion shares fell 4% to $2.23 after-hours.

Write to Josh Beckerman at josh.beckerman@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
ARROWHEAD PHARMACEUTICALS INC 4.23% 27.585 Delayed Quote.112.96%
ORION GROUP HOLDINGS INC 0.44% 2.295 Delayed Quote.-46.85%
S&P GLOBAL INC 1.11% 226.53 Delayed Quote.31.91%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARROWHEAD PHARMACEUTICALS
05/31ARROWHEAD PHARMACEUTICALS : to Present at Upcoming June 2019 Conferences
BU
05/20Arrowhead Shares Up, Orion Group Falls After Hours on S&P SmallCap 600 Moves
DJ
05/08ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
05/08ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
05/08ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2019 Second Quarter Results
BU
05/03ARROWHEAD PHARMACEUTICALS INC : half-yearly earnings release
05/02ARROWHEAD PHARMACEUTICALS : to Present at Upcoming May 2019 Conferences
BU
04/24ARROWHEAD PHARMACEUTICALS : to Webcast Fiscal 2019 Second Quarter Results
BU
04/24ARROWHEAD PHARMACEUTICALS : Begins Triple Combination Cohort in Chronic HBV Pati..
PU
04/19ARROWHEAD PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Cr..
AQ
More news
Financials ($)
Sales 2019 165 M
EBIT 2019 61,5 M
Net income 2019 67,2 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 39,78
P/E ratio 2020
Capi. / Sales 2019 15,5x
Capi. / Sales 2020 28,8x
Capitalization 2 565 M
Chart ARROWHEAD PHARMACEUTICALS INC
Duration : Period :
Arrowhead Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 28,1 $
Spread / Average Target 3,8%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Bruce D. Given Chief Operating Officer
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS INC112.96%2 314
GILEAD SCIENCES7.27%80 909
VERTEX PHARMACEUTICALS4.87%42 680
REGENERON PHARMACEUTICALS-16.74%32 744
GENMAB11.33%10 857
SAREPTA THERAPEUTICS INC16.44%8 523